French biopharmaceutical firm Genkyotex has secured US regulatory approval to conduct a Phase...
- GSK’s Zejula meets primary goal in Phase III ovarian cancer trial
- Trials data suggests Cosentyx from Novartis will change psoriasis market
- Eligibility criteria for clinical trials report challenges in representing LN patients
- Celltrion implements Veeva Vault eTMF to improve visibility into clinical trial activities
- Longboat Clinical launches Patient CONNECT to ease patient recruitment process
Retrophin’s fosmetpantotenate fails in Phase III trial for PKAN
Biopharmaceutical firm Retrophin has reported that the Phase III clinical trial of fosmetpantotenate failed to meet endpoints in pantothenate kinase-associated neurodegeneration (PKAN) patients.
MyoKardia starts dosing hypertrophic cardiomyopathy patients
MyoKardia has commenced dosing of patients in a Phase I trial of small molecule MYK-224 for the treatment of hypertrophic cardiomyopathy (HCM).
Amgen and Allergan report positive data from lymphoma drug trial
Amgen and Allergan have reported positive data from a comparative clinical trial of ABP 798 to treat patients with CD20-positive B-cell non-Hodgkin's lymphoma.
Aimmune begins enrolling egg allergy patients in Phase II study
Aimmune Therapeutics has recruited the first patient in a Phase II clinical trial evaluating investigational biological drug AR201 for the treatment of egg allergy.
Oxurion reports mixed results from Phase IIa DME study
Oxurion has reported top-line results from the Phase IIa clinical trial of THR-317 in combination with ranibizumab to treat diabetic macular edema (DME) patients.
Perspectum and ProPath partner on providing clinical trial expertise
Perspectum and ProPath have collaborated to enable pharmaceutical companies running clinical trials for liver disease to receive pathology and imaging expertise from one contract research organisation (CRO).
ViiV’s long-acting HIV regimen passes late-stage trial
ViiV Healthcare has reported that the Phase III ATLAS-2M clinical trial of its long-acting, two-drug regimen developed to treat HIV infection met its primary endpoint.
Fulcrum launches Phase IIb trial of losmapimod to treat FSHD
Fulcrum Therapeutics has started a Phase IIb clinical trial of losmapimod in patients suffering from facioscapulohumeral muscular dystrophy (FSHD).
Synlogic terminates development of ammonia lowering drug
Synlogic has announced plans to suspend the clinical development of SYNB1020 following negative results from the candidate’s Phase Ib/IIa clinical trial in hyperammonemia patients.
Group K Diagnostics and Health Network agree to start clinical trials
Biotechnology firm Group K Diagnostics (GKD) and laboratory medicine services provider Health Network Laboratories (HNL) have partnered on a clinical trial agreement to bring improved clinical experiences to patients and caregivers.